Veracyte Inc (VCYT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:05 AM ET
Veracyte Inc (VCYT) P/E Ratio & Valuation History
Veracyte (VCYT) trades at 13.3x trailing earnings and 3.3x sales. Its P/S of 3.3x is below its 5-year median of 5.7x. Its forward P/E is 13.1x. The median P/E across 5 similar companies is 48.2x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 1.5% higher over the next year. Its free cash flow yield is 8.4%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 13.3x |
| Forward P/E | 13.1x |
| Price to sales | 3.3x |
| Price to book | 1.3x |
| EV/EBITDA | 12.7x |
| Price to FCF | 11.9x |
| EV/FCF | 10.7x |
| PEG | N/A |
| FCF yield | 8.4% |
Historical Medians
Against its 10-year medians, its P/S is 44.1% below 5.9x and its P/B is 55.2% below 2.9x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.3x | 5.7x | 5.9x |
| P/B | 1.3x | 1.8x | 2.9x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 3.1x in 2017 to 22.2x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $42.10 | 23.5x | 6.4x | 2.6x |
| 2024 | $39.60 | 38.4x | 6.9x | 2.7x |
| 2023 | $27.51 | N/A | 5.5x | 1.9x |
| 2022 | $23.73 | N/A | 5.7x | 1.6x |
| 2021 | $41.20 | N/A | 12.8x | 2.7x |
| 2020 | $48.94 | N/A | 22.2x | 6.7x |
| 2019 | $27.92 | N/A | 10.7x | 5.7x |
| 2018 | $12.58 | N/A | 5.1x | 6.4x |
| 2017 | $6.53 | N/A | 3.1x | 6.0x |
| 2016 | $7.74 | N/A | 3.4x | 4.1x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VCYT
What is VCYT's forward P/E ratio?
Veracyte has a forward P/E ratio of 13.1x.
Is VCYT stock overvalued?
GNG's valuation label for VCYT is Undervalued. Its P/E of 13.3x compares with a median of 48.2x across 5 similar companies.
What is VCYT's price to sales ratio?
Veracyte has a price to sales ratio of 3.3x.
VCYT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts